NOV 24, 2019 11:38 PM PST

The unlikely pain killer

WRITTEN BY: Nouran Amin

Pain can be anything a sunburn, a toothache, or a leg injury to name a few. The relievers that target our pain come in many colors—one being morphine, a widely used opioid.

Learn more about the biology of pain:

Now, a graduate student at West Virginia University, Shane Kaski, is studying how an anti-itch medication can be effective at relieving pain. Specifically, Kaski is examining how the drug ‘nalfurafine’ targets a certain region of our nerve cells that can make morphine more effective. The research could potentially fight against opioid addiction by making patients less reliant on morphine. Essentially, nalfurafine could serve as a ‘supplement’.

"Right now there's a lot of work looking for replacements for opioids, for obvious reasons," said Kaski, a graduate student in the School of Medicine's M.D./Ph.D. program. "Maybe nalfurafine is not so great as a replacement on its own, but maybe it does enough that we could put it together with other opioids and get this dose-sparing effect."

Using a supplemental dose of nalfurafine along with a decreased dose of morphine was found to reduce as much pain as a large dose of morphine alone. The findings of the study were published in the Journal of Pharmacology and Experimental Therapeutics.

"It's possible that you just need a tiny smidgen of nalfurafine with a smidgen of this other addictive drug to get the equivalent pain relief from a larger dose of your addictive drug," he said. "That's what we're seeing in our early work. That's the promise that we saw."

However, there is a paradox—because to fight the opioid addiction, we use another opioid. Nalfurafine, like morphine, is an opioid. But, how exactly is that supposed to work? The answer to that is through pain receptors.

“Why are you going to use another opioid on top of morphine? It comes down to the specifics of the biology of opioid receptors,” says Kaski. "The biggest three opioid receptors you'll hear about are mu, kappa and delta.”

“Nalfurafine is unusual. Even though it's an opioid, it doesn't have a permit to park in mu. Instead it parks in the kappa receptor. Once it does, it alleviates pain while also "putting the brakes on" the reward circuit that can lead to addiction,” Kaski adds.

Source: West Virginia University

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 20, 2022
Microbiology
Rapid AST: A key weapon in the fight against AMR
APR 20, 2022
Rapid AST: A key weapon in the fight against AMR
Despite the dire, well-documented risks of antimicrobial resistance (AMR), which threatens to kill 10 million people a y ...
MAY 19, 2022
Drug Discovery & Development
Experimental Drug Shows Promise Against ALS
MAY 19, 2022
Experimental Drug Shows Promise Against ALS
A new experimental drug known as NU-9 may be more effective in treating ALS than existing FDA-approved drugs. The corres ...
JUN 09, 2022
Plants & Animals
Traditional Indian Medicine Helps Treat and Manage Type 2 Diabetes
JUN 09, 2022
Traditional Indian Medicine Helps Treat and Manage Type 2 Diabetes
Medicine has been practiced for millennia. Despite the dominance of Western medicine, many traditional approaches to tre ...
JUN 22, 2022
Cell & Molecular Biology
A New, Innovative Process for Clarifying and Sterile Filtering Cells for Protein Purification Workflows
JUN 22, 2022
A New, Innovative Process for Clarifying and Sterile Filtering Cells for Protein Purification Workflows
Introduction Centrifugation and filtration have been widely accepted as techniques required for clarifying complex cell ...
JUN 10, 2022
Drug Discovery & Development
The consequences of inappropriate antibiotic prescriptions in children
JUN 10, 2022
The consequences of inappropriate antibiotic prescriptions in children
The discovery of antibiotics in the early 1900’s was one of the most important discoveries in medical history. The ...
JUN 27, 2022
Drug Discovery & Development
Potential Gene Targets Identified for Treating Deafness
JUN 27, 2022
Potential Gene Targets Identified for Treating Deafness
Researchers have identified three mutations of the MINAR2 gene that are linked to deafness. They say that the mutations ...
Loading Comments...